According to the similar characteristics of chronic HBV infection and liver fibrosis, CD8+ T cell‐based therapy can still achieve therapeutic effect in the early stage of HBV‐induced liver fibrosis and cirrhosis. This evidence concerns the gene CD8A and Hepatic fibrosis.